AstraZeneca is a high-quality pharma with a wide moat, 18% margins and strong momentum, but the price of $186.65 is 3.7% above the $179.79 analyst target and RSI is overbought at 80. Cash conversion is only 51% of net income, so the setup favors holding over adding.
Thesis pillars
- Wide Moat Strong Margins↑Improving
- Price Above Analyst Target↑Improving
- Overbought Euphoria Risk↓Deteriorating
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026
AstraZeneca PLC (AZN) Stock Analysis
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $189.01, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 77).
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex,... Read more
Hold if already holding. Not a fresh buy at $189.01, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 77). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 96d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Oct 28, 2026Recent Developments — AstraZeneca PLC
Latest news
- NEWS AstraZeneca PLC (AZN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow (NYSE:AZ — Seeking Alpha Oct 28, 2026 neutral
- NEWS AstraZeneca PLC : JP Morgan reaffirms its Buy rating - marketscreener.com — marketscreener.com Oct 27, 2026 positive
- NEWS Is AstraZeneca (AZN) Stock Cheap? - Yahoo Finance — Yahoo Finance Oct 21, 2026 neutral
- NEWS AstraZeneca PLC : Gets a Buy rating from JP Morgan - marketscreener.com — marketscreener.com Oct 21, 2026 positive
- NEWS Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance — Yahoo Finance Sep 9, 2026 positive
Latest item Oct 28, 2026 · Generated 2026-11-05T11:39:29Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $189.01, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Overbought (RSI 77). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $179.79 reached (−4.9%), stop $180.11 (−4.9%), A.R:R -0.3:1. Score 5.9/10, moderate confidence.
Analyst target $179.79 reached (−4.9% from $189.01); no take-profit level is published. Analyst target $179.79 reached (−4.9%), stop $180.11 (−4.9%), A.R:R -0.3:1. Stop-loss: $180.11.
Analyst target reached - limited upside remaining; Overbought (RSI 77).
AstraZeneca PLC trades at a P/E of 26.7 (forward 16.7). TrendMatrix value score: 5.4/10. Verdict: Hold.
34 analysts rate AZN, with a consensus score of 4.2/5. 12 analysts publish price targets averaging $207.
What does AstraZeneca PLC do?AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization...
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies for rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, USA, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of oral candidates; Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates; and Carterra, Inc. to advances lab-in-the-loop drug discovery through new scientific research collaboration. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is based in Cambridge, the United Kingdom.